CAI Caris Life Sciences, Inc.

QT76

Latest market price

34.33

-1.81-5.01%

Overview Short InterestFilings

CAIQT76Caris Life Sciences, Inc.·NASDAQ

Overview Short InterestFilings

34.33-5.01%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PCVX-0.93%$62.03 KRYS+2.38%$332.29 MDGL-0.31%$430.36 PTGX+0.35%$144.85 TGTX+5.34%$61.18 TWST-11.92%$152.78 TXG-14.03%$70.11 KYMR+3.29%$126.63

Snapshot

Index	—	P/E	95.36	EPS (ttm)	0.36	Insider Own	—	Shs Outstand	282.68M	Perf Week	7.28%

Market Cap	9.70B	Forward P/E	97.88	EPS next Y	0.35	Insider Trans	-0.49%	Shs Float	11.29M	Perf Month	21.09%

Enterprise Value	9.36B	PEG	1.68	EPS next Q	0.03			Short Float	—	Perf Quarter	110.36%

Income	104.00M	P/S	9.80	EPS this Y	—			Short Ratio	2.72	Perf Half Y	85.87%

Sales	990.00M	P/B	16.39	EPS next Y	191.34%	ROA	8.55%	Short Interest	13.59M	Perf YTD	27.24%

Book/sh	2.09	P/C	12.24	EPS next 5Y	56.66%	ROE	18.77%	52W High	36.50 -5.95%	Perf Year	16.65%

Cash/sh	2.81	P/FCF	66.02	EPS past 3/5Y	—	ROIC	14.67%	52W Low	14.19 141.93%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	54.09	Sales past 3/5Y	46.55% 22.53%	Gross Margin	69.66%	Volatility	5.41% 6.51%	Perf 5Y	—

Dividend TTM	—	EV/Sales	9.45	EPS Y/Y TTM	—	Oper. Margin	15.49%	ATR (14)	1.89	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	4.88	Sales Y/Y TTM	85.39%	Profit Margin	10.62%	RSI (14)	62.78	Recom	2.13

Dividend Gr. 3/5Y	—	Current Ratio	5.53	EPS Q/Q	99.57%	SMA20	10.05%	Beta	1.43	Target Price	28.50

Payout	0.00%	Debt/Eq	0.75	Sales Q/Q	45.86%	SMA50	17.72%	Rel Volume	0.76	Prev Close	36.14

Employees	1,846	LT Debt/Eq	0.75	Earnings	Nov 04	SMA200	59.12%	Avg Volume	4.85M	Price	34.33

IPO Date	Jun 18, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-139.19% 10.75%	Net Debt/EBITDA	-2.01	Volume	3,672,180	Change	-5.01%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-27-26	Reiterated	BTIG	Buy	$33 → $38
Sep-09-26	Initiated	UBS	Neutral	$28
Aug-06-26	Reiterated	BTIG	Buy	$32 → $33
Aug-06-26	Reiterated	Evercore ISI Group	Outperform	$25 → $26
Jul-06-26	Reiterated	Evercore ISI Group	Outperform	$38 → $25
May-08-26	Reiterated	Robert W. Baird		$28 → $22
May-08-26	Reiterated	BTIG	Buy	$45 → $32
Apr-10-26	Initiated	Piper Sandler	Neutral	$21
Feb-17-26	Initiated	Baird	Outperform	$26
Jan-05-26	Reiterated	Evercore ISI	Outperform	$40 → $38

Latest News· Times ET

Oct-28-26

Oct-28-2611:01AM

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out forzacks.com

Oct-27-26

Oct-27-2608:50AM

BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38Benzinga

Oct-22-26

Oct-22-2607:00AM

Foundation Medicine Appoints Chadi Nabhan, M.D., MBA, as Chief Medical OfficerYahoo

Oct-19-26

Oct-19-2606:30AM

Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detectionprnewswire.com

Oct-15-26

Oct-15-2608:30AM

Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026prnewswire.com

Oct-14-26

Oct-14-2608:30AM

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026prnewswire.com

Oct-12-26

Oct-12-2606:41PM

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP CredentialsSeekingAlpha

Oct-08-26

Oct-08-2607:07AM

Caris Life Sciences, Inc. $CAI Shares Newly Bought by City Center Advisors LLCdefenseworld.net

Oct-06-26

Oct-06-2609:11AM

S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market TodayBenzinga

Oct-02-26

Oct-02-2603:02PM

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Monthsinvestors.com

Sep-29-26

Sep-29-2603:30AM

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha

Sep-22-26

Sep-22-2602:01PM

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A LookYahoo

Sep-17-26

Sep-17-2610:35AM

Caris Life Sciences: Diagnostics Growth With Room To Runseekingalpha.com

Sep-16-26

Sep-16-2604:56AM

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?zacks.com

Sep-08-26

Sep-08-2606:30AM

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detectprnewswire.com

Company

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	990	812	412	306	—	—	—	—	—
Cost of Goods Sold Incl. D&A	300	273	233	217	—	—	—	—	—
Gross Profit	690	539	179	89	—	—	—	—	—
Selling, General and Administrative Excl. Other	419	392	322	291	—	—	—	—	—
Research and Development	91	45	114	117	—	—	—	—	—
Other Operating Expense	27	57	0	1	—	—	—	—	—
Operating Income	153	45	-257	-320	—	—	—	—	—
Interest Expense	47	57	50	32	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-1	-56	25	10	—	—	—	—	—
Net Income Before Taxes	104	-68	-282	-341	—	—	—	—	—
Income Taxes	0	470	0	0	—	—	—	—	—
Consolidated Net Income	104	-538	-282	-341	—	—	—	—	—
Net Income From Continuing Operations	104	-538	-282	-341	—	—	—	—	—
Net Income	104	-538	-282	-341	—	—	—	—	—
EPS (Recurring)	0.37	-1.91	-2.70	-1.82	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.37	-1.91	-2.70	-1.82	—	—	—	—	—
EPS (Diluted)	0.36	-1.86	-2.70	-1.82	—	—	—	—	—
EBITDA	173	11	-183	-261	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	95.36	—	—	—	—	—	—	—	—
Price To Sales Ratio	9.81	9.37	—	—	—	—	—	—	—
Gross Margin	69.70	66.38	43.45	29.08	—	—	—	—	—
Operating Margin	15.45	5.54	-62.38	-104.58	—	—	—	—	—
Net Margin	10.51	-66.26	-68.45	-111.44	—	—	—	—	—
Shares Outstanding	283	282	255	255	—	—	—	—	—
Market Capitalization	9,715	7,608	—	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Denton John Russel	Officer	Sep 22 '26	Sale	31.82	7,500	238,626	174,855	Sep 23
Brille Brian J	Director, Officer	Sep 17 '26	Sale	30.33	400,000	12,132,080	230,303	Sep 17
Brille Brian J	Director, Officer	Sep 17 '26	Option Exercise	2.44	400,000	976,000	630,303	Sep 17
Spetzler David Baxley	President	Sep 04 '26	Sale	24.76	119,212	2,951,117	1,182,871	Sep 04
Spetzler David Baxley	President	Sep 04 '26	Option Exercise	2.44	250,000	610,000	1,302,083	Sep 04
Spetzler David Baxley	President	Sep 03 '26	Option Exercise	2.44	1,000,000	2,440,000	1,530,083	Sep 04
Spetzler David Baxley	President	Sep 03 '26	Sale	24.86	478,000	11,882,989	1,052,083	Sep 04
HALBERT JON	Director	May 15 '26	Buy	14.56	68,000	990,080	704,598	Jul 13
Vacirca Jeff L	Director	May 11 '26	Buy	16.15	31,050	501,426	49,671	May 12
CASTLEMAN PETER M	Director	Jan 09 '26	Option Exercise	18.60	2,500	46,500	18,629	Jan 13
Power Luke Thomas	Officer	Dec 11 '25	Option Exercise	2.44	62,250	151,890	161,821	Dec 12
Power Luke Thomas	Officer	Dec 11 '25	Sale	26.58	62,250	1,654,462	99,571	Dec 12
Denton John Russel	Officer	Nov 07 '25	Buy	24.09	4,184	100,793	9,184	Nov 10
Spetzler David Baxley	President	Nov 07 '25	Buy	23.85	400	9,540	460,777	Nov 10
PHILLIPS T DANNY	Director	Sep 11 '25	Option Exercise	2.44	100,000	244,000	116,129	Sep 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.